Jaks (janus Kinases) - Infectious Diseases

Relevant Publications

Supersulfides suppress type-Ⅰ and type-Ⅱ interferon responses by blocking JAK/STAT signaling in macrophages.

Issue Release: 2024

Effect of JAK Inhibitors on the Risk of Death in Patients with Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Issue Release: 2024

Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks.

Issue Release: 2024

Cloning and expression analysis of Janus activated kinase family genes from spotted seabass (Lateolabrax maculatus).

Issue Release: 2024

Effect of tofacitinib on the phenotype and activity of Caco‑2 cells in a model of inflammatory bowel disease.

Issue Release: 2024

SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.

Issue Release: 2024

CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models.

Issue Release: 2024

Upadacitinib for the treatment of moderate-to-severe Crohn\'s disease.

Issue Release: 2024

A novel approach to study multi-domain motions in JAK1\'s activation mechanism based on energy landscape.

Issue Release: 2024

Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren\'s disease.

Issue Release: 2024

JAK Inhibitors in Cytokine Storm Syndromes.

Issue Release: 2024

Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors.

Issue Release: 2024

Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.

Issue Release: 2024

JAK inhibitor selectivity: new opportunities, better drugs?

Issue Release: 2024

Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis.

Issue Release: 2024

Revealing innovative JAK1 and JAK3 inhibitors: a comprehensive study utilizing QSAR, 3D-Pharmacophore screening, molecular docking, molecular dynamics, and MM/GBSA analyses.

Issue Release: 2024

Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis.

Issue Release: 2024

Two Prenylated Chalcones, 4-Hydroxyderricin, and Xanthoangelol Prevent Postprandial Hyperglycemia by Promoting GLUT4 Translocation via the LKB1/AMPK Signaling Pathway in Skeletal Muscle Cells.

Issue Release: 2024

Involvement of Janus kinase-dependent Bcl-xL overexpression in steroid resistance of group 2 innate lymphoid cells in asthma.

Issue Release: 2024

Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes.

Issue Release: 2024

When Should One Seek Medical Attention for Fatigue?

How is Protein Targeting Relevant to Infectious Diseases?

Why is the Global Fund Important?

How is ARDS Diagnosed?

How Are Cases and Controls Selected?

What are the Treatment Options for Strep Throat?

What are Vaccines?

How Do Vaccines Work?

How is Rabies Diagnosed?

What are the Causes?

Partnered Content Networks

Relevant Topics